Ms. magazine  -- more than a magazine a movement

SIGN UP FOR MS. DIGEST, JOBS, NEWS AND ALERTS

FEMINIST WIRE NEWSBRIEFS

ABOUT
SEE CURRENT ISSUE
SHOP MS. STORE
MS. IN THE CLASSROOM
FEMINIST DAILY WIRE
FEMINIST RESOURCES
PRESS
JOBS AT MS.
READ BACK ISSUES
CONTACT
RSS (XML)
 
feminist wire | daily newsbriefs

December-12-01

New Drug May Be Effective in Treating Breast Cancer

Studies presented at the San Antonio Breast Cancer Symposium indicate that a new class of hormone therapy may replace Tamoxifen in the treatment of certain types of breast cancers. In post-menopausal women with locally advanced or metastatic breast cancer and also in post-menopausal women with estrogen-receptor and HER-2 positive breast cancer, data suggests that Femara, a drug developed by the Swiss Pharmaceutical company Novartis, is more effective than the commonly used Tamoxifen in shrinking tumor growth. More importantly, in randomized-double blind studies, paid for in part by Novartis, Femara offered a better survival advantage than Tamoxifen. Side effects are essentially the same for both drugs. Femara is an aromatase inhibitor, a drug that prevents the hormone androgen from being converted to estrogen. Tamoxifen is an anti-estrogen, a drug that blocks the effects of already-existing estrogen from exerting its effects at the cellular level.

Research indicates that all breast cancer is not created equal. Future treatment plans will become more and more individually tailored as scientific advancements reveal more about the particulars of certain types of breast cancer. Therefore, it is critical that basic research and clinical trials continue in order to provide maximal therapeutic options for all women.

The Feminist Majority Foundation has launched an emergency campaign for mifepristone (also known as RU-486 and the abortion pill), an important anti-progesterone drug that blocks the effects of progesterone, at the cellular level. Preliminary studies indicate that mifepristone may be effective in treating certain types of breast cancer. Much basic research and clinical trials have come to a standstill however because anti-abortion forces have made it extremely difficult for scientists to even procure the drug to explore its exciting non-abortion medical potential.

Media Resources: Novartis; Associated Press, 12/11/01; Feminist Majority Foundation


© Feminist Majority Foundation, publisher of Ms. magazine

If you liked this story, consider making a tax-deductible donation to support Ms. magazine.

 

 

Send to a Friend
Their
Your
Comments
(optional)


More Feminist News

7/27/2015 Senate Majority Leader Mitch McConnell Blocked Efforts to Defund Planned Parenthood - An attempt in the Senate to defund Planned Parenthood by Mike Lee (R-UT) was blocked this weekend by Senate Majority Leader Mitch McConnell (R-KY). Lee tried to attach the elimination of federal funds for Planned Parenthood to a vote for highway legislation, a move which was rejected by McConnell as out of order. Republican legislators have redoubled their efforts to block funding for Planned Parenthood since the release of two heavily edited clandestine videos of different PPFA employees taken without their knowledge. . . .
 
7/27/2015 "After Tiller" Was Nominated For An Emmy - Documentary film After Tiller was nominated for two Emmy Awards: Best Documentary, and Outstanding Coverage of a Current News Story. The Point of View (POV) documentary follows the aftermath of the murder of Dr. . . .
 
7/24/2015 Katherine Spillar Urges Cleveland to Dramatically Increase Hiring of Women Police to Mitigate Police Violence - In a well-received speech at the City Club of Cleveland today, Katherine Spillar, Executive Director of the Feminist Majority Foundation urged Cleveland city officials to dramatically increase the hiring of women police officers as a way to decrease police brutality incidents. Following a number of high profile police killings in Cleveland of African Americans, and an eight-month investigation by the US Attorney's office of the Northern District of Ohio, the City of Cleveland has now entered into a Consent Decree that requires numerous reforms in how the city oversees and investigates police operations, including training in use of force. "Among the most important reforms mandated by the consent decree - and the most easily overlooked - are the changes the Cleveland Division of Police must make in its recruitment and hiring practices, said Spillar. . . .